Navigation Links
New ACO Reinsurance Program Launched by Star Line Group, U.S. Advisors and Ascendent Care
Date:11/8/2011

MINNEAPOLIS, Nov. 8, 2011 /PRNewswire/ -- Star Line Group, U.S. Advisors and Ascendent Care, announced today a new reinsurance program in response to the final regulations published recently by CMS for the Medicare ACO Shared Savings Program.

"We recognize the unique requirements of organizations that want to participate in the ACO Shared Savings Program and their need to moderate their downside risk in an affordable fashion," notes Robert Tierney, Star Line President.  "We have been tracking this issue from the draft regulations and our team has been working on the development of this new program for a number of months."

The ACO Reinsurance program recognizes the delayed cash flow compared to traditional health care financing mechanisms, as well as other unique aspects of the Shared Savings Program.  It is designed to protect an ACO's capital as they take risk on Medicare members.  

"Our reinsurance program really takes a lot of pressure off the downside risk and the cash flow requirements of the ACO," notes Terry Chesser, President of U.S. Advisors. 

"We have studied the environment closely and believe that we have an ideal program for those ACOs who have the motivation to improve quality and efficiency, yet may not have the deepest balance sheets and would otherwise not be able to take advantage of the Track 2 profit sharing rewards,"  explains Dan Johnson, Star Line Vice President.  

Mike Barrett, CEO of Ascendent Care, further adds "Ascendent is pleased to be involved in the due diligence review of ACOs under consideration for reinsurance, as well as the ongoing reporting and monitoring activities.  It is clear that this will expand the number of organizations that can step up to meet the mission and goals of the Medicare ACO Shared Savings Progr
'/>"/>

SOURCE Star Line Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NephroGenex Reaches Agreement with the FDA on a Subpart H Phase 3 Program for Pyridorin™
2. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
3. "PATH B": A Comprehensive Support Programme in Europe for Patients Diagnosed With Chronic Hepatitis B Launched
4. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
5. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
6. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
7. Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match®
8. Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs
9. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
10. BD Biosciences Announces Winners of Research Grant Program
11. University of Houston receives NSF grant for high school teachers program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... (Nasdaq: SGMO ) announced today that Philip Gregory, ... on the progress of,Sangamo,s ZFP Therapeutic development programs and ... on Wednesday, October 10, 2007,at the BIO InvestorForum in ... and may be accessed via a link on,the Sangamo ...
... Thompson, President,and CEO of Oncolytics Biotech Inc. (TSX: ... the Company at the 15th annual BioPartnering Europe,conference ... 9 a.m. The conference,will be held at the ... About Oncolytics Biotech Inc. Oncolytics is ...
... (Nasdaq: MSHL ) will present at the BIO ... Thursday, October 11, 2007 at 12:00 pm. About ... MSHL ) is a specialist oncology company,focused on the ... flavonoid technology platform which has generated a,number of novel ...
Cached Biology Technology:Sangamo BioSciences to Present at the 2007 BIO InvestorForum 2Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 3
(Date:9/2/2014)... in stride; others are done in by it. New ... of this so-called stress gap in mice with very ... researchers to better understand the development of psychiatric disorders ... animal has unique experiences as it goes through its ... alter the expression of genes, and as a result, ...
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
(Date:9/1/2014)... It may be possible to train the brain to ... to new research by scientists at the Jean Mayer ... at Tufts University and at Massachusetts General Hospital. Published ... , a brain scan study in adult men and ... addictive power of unhealthy food while also increasing preference ...
Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3Training your brain to prefer healthy foods 2
... think a city would provide a good home for bats ... buildings. But researchers at the University of Calgary made the ... for these animals. "I was really surprised," says Dr. ... biological sciences at the University of Calgary and lead author ...
... CHAMPAIGN, lll. Blood clotting is a complicated business, ... to injury. In a new study, researchers report that they ... interaction that is vital to blood clotting. This interaction ... baffled scientists for decades. The study appears ...
... State University shows that so-called biodegradable products are likely ... are releasing a powerful greenhouse gas as they break ... utensils, are broken down in landfills by microorganisms that ... a paper describing the research and professor and head ...
Cached Biology News:Big city holds empty promise for bats 2Team solves decades-old molecular mystery linked to blood clotting 2Team solves decades-old molecular mystery linked to blood clotting 3Study: Biodegradable products may be bad for the environment 2
... , Maintenance 112 days/each ... , Immunizations/Boost injections x5 /each ... , Production bleed (25 ml blood ... ~ 100 ml blood (~50 ml serum) x1 each ...
chk 1 kinase...
... Cell Functional Identification Kit contains specially ... used for the short-term maintenance, differentiation, ... induction of NSCs into astrocyte, neuron ... consisting of mouse anti-human Nestin, mouse ...
Rat Antibody to Kinase Suppressor Of Ras Recognises the kinase suppressor of Ras (KSR). Immunogen: Recombinant human KSR protein Specificity: human kinase supressor of Ras...
Biology Products: